Skip to content

Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia

Study of the Clinical, Microbiological, and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the Borrelia National Reference Center

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07335965
Acronym
BORRECUR
Enrollment
25
Registered
2026-01-13
Start date
2025-02-19
Completion date
2026-10-19
Last updated
2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borrelia Recurrentis Infection

Keywords

Borrelia Infections, Borrelia Recurrentis Infection

Brief summary

Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species. A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Minor or adult subject * Having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg

Exclusion criteria

\- Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Clinical and biological description of cases of recurrent imported borreliosisUp to 12 yearsThis study does not include any evaluation, but simply describes cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, and treatment.

Countries

France

Contacts

Primary ContactÉmilie TALAGRAND-REBOUL, MD
emilie.talagrandreboul@chru-strasbourg.fr33 3 69 55 14 57

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026